Thermalin Inc.

Waban, MA · Founded 2016 · Medtech · Defunct

Postage-stamp-sized closed-loop insulin patch pump with optional counter-regulatory medication delivery for automatic hyperglycemia management

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · thermalin.com

Sector: Medtech
Headquarters: Waban, MA
Founded: 2016
Latest Form D: $2.3M, Aug 2019
Total capital: $11.1M

Federal grants: $3.8M; 6 awards · 2017–2021; Rank in peer group#420 of 542
Private capital raised: $7.2M; 2 Form D · last Aug 2019; 87 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 1; 9 pending · first 2020; Rank in peer group#106 of 542

Capital timeline

Latest events

Jul 2021Federal grantHealth and Human S · Phase II · Disrupting Insulin Delivery with a Novel, Stabilized Insulin that is Ultra-rapid at U100 or U500$1.6M
Sep 2020Federal grantHealth and Human S · Phase II · Disrupting Insulin Delivery with a Novel, Stabilized Insulin that is Ultra-rapid at U100 or U500$1.4M
Aug 2019Private capital raisedForm D · SEC · 2nd filing$2.3M
Apr 2019Federal grantHealth and Human S · Phase I · StampPump: Proof of Principle for a Disruptive Insulin Delivery Technology$276K
Mar 2019Federal grantDefense · Phase I · StampPump: a Postage-Stamp Sized Autonomous Glycemic Control Mechanism for Patients Suffering Glycemic Abnormalities as a Result of Critical Illnesses$224K
Nov 2017Private capital raisedForm D · SEC · 1st filing$4.9M
Apr 2017Federal grantHealth and Human S · Phase I · Enabling implantable artificial pancreas pumps with heat-stable, ultra-rapid insulin$223K

Show 1 earlier federal award

Apr 2017Federal grantHealth and Human S · Phase I · Optimizing diabetes therapy: re-engineering insulin as a biased agonist$109K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

8months

from Thermalin Inc.’s first federal award to its first private round.

First federal award · Apr 2017: Health and Human S · $109K
First Form D · Nov 2017: $4.9M · 1st Form D
Awards before first raise: 2 awards

An association in public records, not a cause or a prediction.

Standing among 542 peers

Line = median

Medtech · Device

Federal grantsBelow median
Granted patents#106 · top 20%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

David C. SweeneyDirectorNamed in SEC Form D filings
John BrooksDirectorNamed in SEC Form D filings
John PicerneDirectorNamed in SEC Form D filings
Katherine BowdishDirectorNamed in SEC Form D filings
Masako HashimotoDirectorNamed in SEC Form D filings
Richard BerensonExecutive Officer, Director, PromoterNamed in SEC Form D filings

Show all 7 people

Tim C. XiaoDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 10

Sep 15, 2022PendingInsulin Analogues With Glucose Regulated Conformational SwitchUSPTOApplication 17630258
Dec 16, 2021PendingRapid Action Insulin Formulations And Pharmaceutical Delivery SystemsUSPTOApplication 17335141
May 7, 2020PendingRapid Action Insulin Formulations And Pharmaceutical Delivery SystemsUSPTOApplication 16732606

Show all 10 patent records

Insulin Analogues With Glucose Regulated Conformational SwitchSep 15, 2022 · Application 17630258Pending
Rapid Action Insulin Formulations And Pharmaceutical Delivery SystemsDec 16, 2021 · Application 17335141Pending
Rapid Action Insulin Formulations And Pharmaceutical Delivery SystemsMay 7, 2020 · Application 16732606Pending
Rapid Action Insulin Formulations And Pharmaceutical Delivery SystemsFeb 18, 2020 · US 10,561,711Granted
Rapid Acting Insulin Analogues And CompositionsApplication 62984165Pending
Agent Delivery Systems, Devices, And MethodsApplication PCTUS2020058192Pending
Insulin Analogues With Glucose Regulated Conformational SwitchApplication PCTUS2020044415Pending
Insulin Analogues With Glucose Regulated Conformational SwitchApplication 62931933Pending
Insulin Analogues With Glucose Regulated Conformational SwitchApplication 62880945Pending
Insulin Analogues With Glucose Regulated Conformational SwitchApplication 62934774Pending

Sterilucent, Inc.Similar federal contract value in Medtech · null in contracts
CardioNXT, Inc.Similar federal contract value in Medtech · null in contracts
Eyeguide, Inc.Similar federal contract value in Medtech · null in contracts
Mainstay Medical, Inc.Similar federal contract value in Medtech · null in contracts
NAVIGATE SURGICAL TECHNOLOGIES INC.Similar federal contract value in Medtech · null in contracts
Nucs AI Inc.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.